Heterodimeric antibodies that bind CD3 and tumor antigens

Patent metadata

Field	Value
Publication number	US-11945880-B2
Application number	US-202117542342-A
Country	US
Kind code	B2
Filing date	Dec 3, 2021
Priority date	Nov 26, 2014
Publication date	Apr 2, 2024
Grant date	Apr 2, 2024

Abstract

The present invention is directed to novel heterodimeric antibodies.

First claim

What is claimed is:

1. A composition comprising a CD3 binding domain, said CD3 binding domain comprising a variable heavy domain and a variable light domain selected from the following:
a) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:20, a vhCDR2 having the amino acid sequence of SEQ ID NO:21, and a vhCDR3 having the amino acid sequence of SEQ ID NO:22; and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO:24, a vlCDR2 having the amino acid sequence of SEQ ID NO:25, and a vlCDR3 having the amino acid sequence of SEQ ID NO:26;
b) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:29, a vhCDR2 having the amino acid sequence of SEQ ID NO:30, and a vhCDR3 having the amino acid sequence of SEQ ID NO:31; and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO:33, a vlCDR2 having the amino acid sequence of SEQ ID NO:34, and a vlCDR3 having the amino acid sequence of SEQ ID NO:35;
c) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:38, a vhCDR2 having the amino acid sequence of SEQ ID NO:39, and a vhCDR3 having the amino acid sequence of SEQ ID NO:40; and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO:42, a vlCDR2 having the amino acid sequence of SEQ ID NO:43, and a vlCDR3 having the amino acid sequence of SEQ ID NO:44; and
d) a variable heavy domain comprising a vhCDR1 having the amino acid sequence of SEQ ID NO:47, a vhCDR2 having the amino acid sequence of SEQ ID NO:48, and a vhCDR3 having the amino acid sequence of SEQ ID NO:49; and a variable light domain comprising a vlCDR1 having the amino acid sequence of SEQ ID NO:51, a vlCDR2 having the amino acid sequence of SEQ ID NO:52, and a vlCDR3 having the amino acid sequence of SEQ ID NO:53.

2. The CD3 binding domain according to claim 1 , wherein the binding domain is a scFv.

3. The CD3 binding domain according to claim 1 , wherein the variable heavy domain has the amino acid sequence of SEQ ID NO:19, and the variable light domain has the amino acid sequence of SEQ ID NO:23.

4. The CD3 binding domain according to claim 1 , wherein the variable heavy domain has the amino acid sequence of SEQ ID NO:28, and the variable light domain has the amino acid sequence of SEQ ID NO:32.

5. The CD3 binding domain according to claim 1 , wherein the variable heavy domain has the amino acid sequence of SEQ ID NO:37, and the variable light domain has the amino acid sequence of SEQ ID NO:41.

6. The CD3 binding domain according to claim 1 , wherein the variable heavy domain has the amino acid sequence of SEQ ID NO:46, and the variable light domain has the amino acid sequence of SEQ ID NO:50.

7. The CD3 binding domain of claim 2 , wherein the scFv has the amino acid sequence of SEQ ID NO:36.

8. The CD3 binding domain of claim 2 , wherein the scFv has the amino acid sequence of SEQ ID NO:45.

9. The CD3 binding domain of claim 2 , wherein the scFv has the amino acid sequence of SEQ ID NO:54.

10. The CD3 binding domain of claim 2 , wherein the scFv has the amino acid sequence of SEQ ID NO:27.

11. A nucleic acid composition encoding the scFv of claim of any one of claims 7 - 9 , and 10 .

12. An expression vector comprising the nucleic acid composition of claim 11 .

13. A host cell comprising the expression vector of claim 11 .

Assignees

• Xencor Inc

Inventors

• Bernett Matthew J
• Moore Gregory
• Desjarlais John
• Chu Seung
• Rashid Rumana
• Muchhal Umesh
• Lee Sung-Hyung

Classifications

• C07K16/468 Primary

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title

• C07K16/2809

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• C07K16/2866

  against receptors for cytokines, lymphokines, interferons · CPC title

• C07K16/2887

  against CD20 · CPC title

• C07K16/2896

  against molecules with a "CD"-designation, not provided for elsewhere · CPC title